<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>347</serviceExecutionTime><Drug id="75438"><DrugName>revusiran</DrugName><DrugNamesKey><Name id="43037991">revusiran</Name></DrugNamesKey><DrugSynonyms><Name><Value>TTR GalNAc-siRNA</Value></Name><Name><Value>SAR-438714</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>revusiran</Value><Types><Type>INN</Type></Types></Name><Name><Value>ALN-TTRsc</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29927">Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="16299">Sanofi Genzyme</Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="75438" type="Drug"><TargetEntity id="758378" type="siDrug">Revusiran</TargetEntity></SourceEntity><SourceEntity id="16299" type="Company"><TargetEntity id="4295906583" type="organizationId">Genzyme Corp</TargetEntity></SourceEntity><SourceEntity id="29927" type="Company"><TargetEntity id="4295916167" type="organizationId">Alnylam Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1143" type="ciIndication"><TargetEntity id="E85" type="ICD10"/><TargetEntity id="277.3" type="ICD9"/><TargetEntity id="10002022" type="MEDDRA"/><TargetEntity id="D000686" type="MeSH"/><TargetEntity id="69" type="ORPHANET"/><TargetEntity id="-1448456586" type="omicsDisease"/><TargetEntity id="716" type="siCondition"/></SourceEntity><SourceEntity id="22390" type="Action"><TargetEntity id="5536" type="Mechanism">TTR Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1143">Amyloidosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="22390">TTR gene inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="26035">siRNA agent</Action><Action id="2659">Cardioprotectant</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="262">Oligonucleotide conjugated</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-04-10T06:07:20.000Z</LastModificationDate><ChangeDateLast>2016-11-26T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-10T04:23:54.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29927" linkType="Company"&gt;Alnylam Pharmaceuticals&lt;/ulink&gt; and licensee &lt;ulink linkID="16299" linkType="Company"&gt;Genzyme&lt;/ulink&gt; (a &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt; company) were developing revusiran  (SAR-438714; ALN-TTRsc), a second-generation siRNA therapy targeting the transthyretin (TTR) gene, delivered using a GalNAc-conjugate delivery approach and subcutaneous administration, for the potential treatment of TTR-mediated  familial amyloidotic cardiomyopathy  (FAC) [&lt;ulink linkID="1253104" linkType="Reference"&gt;1253104&lt;/ulink&gt;], [&lt;ulink linkID="1253292" linkType="Reference"&gt;1253292&lt;/ulink&gt;], [&lt;ulink linkID="1333607" linkType="Reference"&gt;1333607&lt;/ulink&gt;], [&lt;ulink linkID="1551348" linkType="Reference"&gt;1551348&lt;/ulink&gt;], [&lt;ulink linkID="1575627" linkType="Reference"&gt;1575627&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2014, Alnylam  initiated a phase III trial (ENDEAVOUR) in FAC [&lt;ulink linkID="1620335" linkType="Reference"&gt;1620335&lt;/ulink&gt;]; in October 2016, following the  recommendations of the Data Monitoring Committee (DMC)  that dosing in the ENDEAVOUR trial be suspended, Alnylam decided to discontinue development of revusiran; at that time, Sanofi was also  presumed   to have discontinued its development activities [&lt;ulink linkID="1804620" linkType="Reference"&gt;1804620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was also being developed for TTR amyloidosis patients with familial amyloidotic polyneuropathy (FAP); in October 2015, a phase II study for FAP was initiated in Europe [&lt;ulink linkID="1714776" linkType="Reference"&gt;1714776&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also developing &lt;ulink linkID="61779" linkType="Drug"&gt;ALN-TTR01&lt;/ulink&gt; and &lt;ulink linkID="67037" linkType="Drug"&gt;patisiran&lt;/ulink&gt;  (ALN-TTR02) for TTR amyloidosis.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2015, Sanofi stated that the compound patent would expire in 2032 in the US, EU and Japan [&lt;ulink linkID="1642788" linkType="Reference"&gt;1642788&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2015, the FDA 	granted revusiran Orphan Drug status for the treatment of TTR-mediated amyloidosis [&lt;ulink linkID="1661782" linkType="Reference"&gt;1661782&lt;/ulink&gt;], [&lt;ulink linkID="1662561" linkType="Reference"&gt;1662561&lt;/ulink&gt;]. In December 2015, revusiran was granted FDA Fast Track designation for treating TTR-mediated amyloidosis [&lt;ulink linkID="1735094" linkType="Reference"&gt;1735094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2014, the EMA's COMP recommended granting the product Orphan designation for the treatment of TTR-mediated amyloidosis [&lt;ulink linkID="1535565" linkType="Reference"&gt;1535565&lt;/ulink&gt;], [&lt;ulink linkID="1542198" linkType="Reference"&gt;1542198&lt;/ulink&gt;]; in April 2014, Orphan designation was granted [&lt;ulink linkID="1559026" linkType="Reference"&gt;1559026&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2014, a randomized, double-blind, placebo-controlled   study  (&lt;ulink linkID="218366" linkType="Protocol"&gt;NCT02319005&lt;/ulink&gt;; ALN-TTRSC-004; ENDEAVOUR) was initiated in the US, Canada and Europe in patients (n = 200) with FAC to evaluate the efficacy and safety of revusiran [&lt;ulink linkID="1620335" linkType="Reference"&gt;1620335&lt;/ulink&gt;], [&lt;ulink linkID="1620492" linkType="Reference"&gt;1620492&lt;/ulink&gt;], [&lt;ulink linkID="1622673" linkType="Reference"&gt;1622673&lt;/ulink&gt;]. The primary endpoints were change compared to baseline in 6-minute walk distance (6-MWD) and the % reduction in serum TTR between revusiran and placebo groups at 18 months. All patients had a TTR mutation, including V122I or other mutations, and revusiran was administered sc at 500 mg qd for 5 days then weekly for 18 months. Patients who completed the trial would be eligible to enroll in a phase III, open-label extension study (ENDEAVOUR-OLE) [&lt;ulink linkID="1661782" linkType="Reference"&gt;1661782&lt;/ulink&gt;], [&lt;ulink linkID="1786513" linkType="Reference"&gt;1786513&lt;/ulink&gt;]. In August 2016, enrollment of 206 patients was  completed and data were expected in early 2018 [&lt;ulink linkID="1786513" linkType="Reference"&gt;1786513&lt;/ulink&gt;]. In October 2016, the DMC recommended that dosing be suspended following a review of unblinded data showing  new onset or worsening peripheral neuropathy; the company's review of unblinded data showed increased mortality in the revusiran arm  compared with placebo. Alnylam halted all dosing [&lt;ulink linkID="1804620" linkType="Reference"&gt;1804620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2015, an open-label, single group assignment, safety/efficacy, phase II study (&lt;ulink linkID="245003" linkType="Protocol"&gt;NCT02595983&lt;/ulink&gt;; ALN-TTRSC-005) was initiated in France, Germany, Portugal, Spain, Sweden and the UK, in patients (expected n = 12) with transthyretin-mediated familial amyloidotic polyneuropathy with disease progression post-orthotopic liver transplant. The primary endpoint was the percentage reduction in serum transthyretin levels at 6 months. At that time, the study was expected to complete in December 2017. In February 2017,  the trial was completed [&lt;ulink linkID="1714776" linkType="Reference"&gt;1714776&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, an open-label extension study (&lt;ulink linkID="216083" linkType="Protocol"&gt;NCT02292186&lt;/ulink&gt;; ALN-TTRSC-003) was initiated in the US and the UK to evaluate  the long-term safety, efficacy and pharmacokinetics   of revusiran in patients (n = 25) with TTR cardiac amyloidosis who had previously received the drug. The trial was expected to complete in June 2017 [&lt;ulink linkID="1641941" linkType="Reference"&gt;1641941&lt;/ulink&gt;]. By August 2015, three patients had discontinued due to injection site reactions [&lt;ulink linkID="1684493" linkType="Reference"&gt;1684493&lt;/ulink&gt;]. In November 2015, initial 6-month data were reported. The drug showed sustained TTR knockdown representing the longest dosing experience reported to date for target gene knockdown with a GalNAc-siRNA conjugate. In majority of patients, 6 minute walk distance results at 6 months were stable compared with baseline, and revusiran was well tolerated out to 10 months of administration [&lt;ulink linkID="1711543" linkType="Reference"&gt;1711543&lt;/ulink&gt;].   In July 2016, 12-month data from 16 patients were presented at the XV International Symposium on Amyloidosis in Uppsala, Sweden. Five of the nine patients evaluable for 6MWD showed generally stable results, with mean change of -14 ± 8 meters; the mean change in all nine evaluable patients was -73 ± 26 meters [&lt;ulink linkID="1777625" linkType="Reference"&gt;1777625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, an open-label, multidose, single-group-assigned, interventional phase II study (&lt;ulink linkID="161023" linkType="Protocol"&gt;NCT01981837&lt;/ulink&gt;; ALN-TTRSC-002) was planned to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics  of revusiran in patients (expected n = 15) with TTR cardiac amyloidosis in the US and the UK. At that time, the trial was expected to be completed in December 2014 [&lt;ulink linkID="1506853" linkType="Reference"&gt;1506853&lt;/ulink&gt;]. In December 2013,  the trial was initiated [&lt;ulink linkID="1509283" linkType="Reference"&gt;1509283&lt;/ulink&gt;]. In November 2014, enrollment (n = 26) was completed in the pilot trial [&lt;ulink linkID="1608852" linkType="Reference"&gt;1608852&lt;/ulink&gt;]. Also in November 2014, preliminary  data were presented at the   AHA Scientific Sessions in Chicago, IL. Revusiran was found to be generally well tolerated in TTR cardiac amyloidosis patients and demonstrated clinical activity with an up to 98.2% knockdown of serum TTR. There was a similar knockdown effects toward wild type and mutant TTR protein within V122I genotype patients. Over 5 week treatment, there were no significant changes observed in a number of exploratory clinical measurements. The most common adverse event was mild injection site reactions (23%) and a low incidence of transient mild liver function test changes (15%) that resolved without discontinuation. One patient had an approximate 4-fold elevation in liver transaminases that was deemed a serious adverse event (SAE) and mild in severity, which also resolved during continued dosing. There was also a low incidence (15%) of mild, transient, and clinically insignificant monocytosis (n = 4). There were no discontinuations and no significant changes in renal function or any other laboratory chemistry or hematologic parameters  [&lt;ulink linkID="1612384" linkType="Reference"&gt;1612384&lt;/ulink&gt;]. In March 2015, complete results were presented at the American College of Cardiology (ACC) Annual Scientific Session in San Diego, CA, showing treatment was generally well tolerated in  both patients with FAC and those with senile systemic amyloidosis, a form of TTR cardiac amyloidosis. Consistent with previous reports, patients achieved a 98.2% knockdown of serum TTR after 5 weeks of treatment, with a mean maximum knockdown of 85.9% [&lt;ulink linkID="1641628" linkType="Reference"&gt;1641628&lt;/ulink&gt;]. In March 2015, data from 18 patients in the trial, were presented at the 64th American College of Cardiology Annual Scientific Sessions in San Diego, CA. Data demonstrated that treatment with ALN-TTRSC was well-tolerated and serum transthyretin lowering was &amp;gt; 85% [&lt;ulink linkID="1647935" linkType="Reference"&gt;1647935&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2012, the company planned to file an IND in the second half of 2012, with data expected in the first half of 2013 [&lt;ulink linkID="1253104" linkType="Reference"&gt;1253104&lt;/ulink&gt;], [&lt;ulink linkID="1253292" linkType="Reference"&gt;1253292&lt;/ulink&gt;]. In August 2012, the company reported that sc administration of revusiran was expected in human studies at a dose volume of approximately 1 ml [&lt;ulink linkID="1313489" linkType="Reference"&gt;1313489&lt;/ulink&gt;]. In January 2013, the company filed a CTA with the UK Medicines and Healthcare products regulatory agency to initiate a  randomized, double-blind, placebo-controlled, single and multi-dose, dose-escalation phase I study, expected to   enroll up to 40 healthy volunteer subjects. Following approval of the CTA, the company expected to initiate the trial in early 2013, and planned to report the data in mid-2013 [&lt;ulink linkID="1354040" linkType="Reference"&gt;1354040&lt;/ulink&gt;]; in March 2013, dosing in the safety and tolerability phase I trial was initiated in UK [&lt;ulink linkID="1393036" linkType="Reference"&gt;1393036&lt;/ulink&gt;]. In July 2013, the company reported topline data from the trial, showing that revusiran produced significant knockdown of serum TTR protein levels of &amp;gt;80% in healthy subjects and was safe and well tolerated. Results from the study were scheduled to be presented in September 2013 at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Orlando, FL [&lt;ulink linkID="1451343" linkType="Reference"&gt;1451343&lt;/ulink&gt;]. In September 2013, positive interim results from 28 subjects were presented,  demonstrating that revusiran showed rapid, dose-dependent, consistent, and durable knockdown of serum TTR levels in the multi-dose cohorts (n = 12) of 2.5, 5 and 	10 mg/kg which was 70.6, 93.3 and 94.0%, respectively as compared to 58.2, 87.5 and 92.4% in the same dose levels for nadir, respectively [&lt;ulink linkID="1479899" linkType="Reference"&gt;1479899&lt;/ulink&gt;]. In October 2014, additional  data were presented at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held  in San Diego, CA.   Knockdown of TTR levels were observed  with 7.5 mg/kg cohort (n = 6) and showed a mean  maximum TTR knockdown of 87.5% and a maximum  knockdown of 96.2% [&lt;ulink linkID="1602090" linkType="Reference"&gt;1602090&lt;/ulink&gt;]. In August 2016, further clinical data were presented at the 252nd ACS meeting in Philadelphia, PA. AUC of 19405 microg/ml.day was observed with revusiran treatment [&lt;ulink linkID="1788727" linkType="Reference"&gt;1788727&lt;/ulink&gt;].	&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In September 2014, a prospective, multicenter, screening  study (&lt;ulink linkID="212062" linkType="Protocol"&gt;NCT02252653&lt;/ulink&gt;; DISCOVERY) was initiated to investigate the occurance of TTR mutations in patients (expected n = 1000) suspected with cardiac amyloidosis [&lt;ulink linkID="1596721" linkType="Reference"&gt;1596721&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2014, preclinical data were presented at the International Symposium on Amyloidosis in Indianapolis, IN. In transgenic mice expressing the amyloidogenic mutant human V30M TTR, revusiran treatment achieved 80% TTR suppression at steady state leading to the regression of TTR deposits in multiple tissues. In mice were treated with LNP-siTTR (a lipid nanoparticle-formulated TTR-specific siRNA) and tafamids, at a dose that achieved a robust knockdown of serum TTR by &amp;gt;95 and 100%, the TTR depositions were reduced by mean levels &amp;gt;75 and 35% and maximum levels of &amp;gt;95 and 64%, respectively. Revusiran at 10 mg/kg achieved more rapid and greater TTR knockdown at 100-fold lower target tissue exposure when compared with a TTR-specific antisense oligonucleotide [&lt;ulink linkID="1551570" linkType="Reference"&gt;1551570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, data presented at  the 20th International Roundtable on Nucleosides, Nucleotides and Nucleic Acids in  Montreal, Canada,  demonstrated that 80% TTR reduction at doses as low as 2.5 mg/kg was observed when revusiran was administered in a loading regimen of once-daily for five days, followed by a maintenance regimen of once a week for four weeks.  In single dose and multi-dose preclinical safety studies in rodents and non-human primates, the therapy was found to be safe and well-tolerated even at 300 mg/kg, with therapeutic index exceeding 100-fold [&lt;ulink linkID="1313489" linkType="Reference"&gt;1313489&lt;/ulink&gt;]. In October 2012, additional data were presented at the 8th Oligonucleotide Therapeutics Society meeting in Boston, MA [&lt;ulink linkID="1337825" linkType="Reference"&gt;1337825&lt;/ulink&gt;]. In December 2013, further data were presented at the 12th US-Japan Symposium on Drug Delivery Systems in Lahaina, HI demonstrating that weekly dosing transthyretin mRNA in mice showed a steady TTR knockdown of 50% in the 1.0 mg/kg dose level which was sustained for 196 days when analyzed [&lt;ulink linkID="1510440" linkType="Reference"&gt;1510440&lt;/ulink&gt;]. In October 2014, data demonstrated that No Observed Adverse Effect Level (NOAEL) was observed with 30 mg/kg. The drug was well tolertaed in a nine-month non-human primate study  [&lt;ulink linkID="1602090" linkType="Reference"&gt;1602090&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2012, preclinical studies had demonstrated that once-weekly dosing of revusiran enables robust and sustained silencing of TTR over a multi-week period [&lt;ulink linkID="1253104" linkType="Reference"&gt;1253104&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Alnylam's proprietary N-acetylgalactosamine (GalNAc)-siRNA conjugate delivery platform provides targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor (ASGPR) [&lt;ulink linkID="1451343" linkType="Reference"&gt;1451343&lt;/ulink&gt;]. The GalNAc-siRNA conjugate revusiran comprises synthetic double-stranded siRNA oligonucleotide directed against TTR mRNA, covalently linked to a ligand containing three GalNAc residues [&lt;ulink linkID="1535565" linkType="Reference"&gt;1535565&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, the EMA's Pediatric Committee (PDCO) agreed on a product-specific waiver for the drug, recommending the submission of pediatric clinical data be waived in all subsets of the pediatric population [&lt;ulink linkID="1722938" linkType="Reference"&gt;1722938&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16299">Sanofi Genzyme</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16299">Sanofi Genzyme</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16299">Sanofi Genzyme</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="1143">Amyloidosis</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1804620" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2013-03-18T00:00:00.000Z</StatusDate><Source id="1393036" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2013-12-16T00:00:00.000Z</StatusDate><Source id="1509283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2013-12-16T00:00:00.000Z</StatusDate><Source id="1509283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2014-12-11T00:00:00.000Z</StatusDate><Source id="1620335" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16299">Sanofi Genzyme</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1661782" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16299">Sanofi Genzyme</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1661782" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2014-12-11T00:00:00.000Z</StatusDate><Source id="1620335" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16299">Sanofi Genzyme</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1661782" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2014-12-11T00:00:00.000Z</StatusDate><Source id="1620335" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1143">Amyloidosis</Indication><AwardedIndication>Treatment of TTR-mediated amyloidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-02-12T00:00:00.000Z</MileStoneDate><Source id="1735094" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3399">Familial amyloid neuropathy</Indication><AwardedIndication>Treatment of transthyretin amyloidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-05-18T00:00:00.000Z</MileStoneDate><Source id="1662561" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1143">Amyloidosis</Indication><AwardedIndication>Treatment of ATTR amyloidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2014-11-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1143">Amyloidosis</Indication><AwardedIndication>Treatment of ATTR amyloidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-04-29T00:00:00.000Z</MileStoneDate><Source id="1559026" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1143">Amyloidosis</Indication><AwardedIndication>Treatment of ATTR amyloidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2014-03-12T00:00:00.000Z</MileStoneDate><Source id="1542198" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-02761"><Name>TTR gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="142304" title="Genzyme to develop Alnylam's RNAi therapeutics worldwide, excluding North America and Western Europe                    "/></Deals><PatentFamilies><PatentFamily id="2530631" number="WO-2013074974" title="Modified RNAi agents"/><PatentFamily id="3166593" number="WO-2016057693" title="Methods and compositions for inhalation delivery of conjugated oligonucleotide"/><PatentFamily id="3207787" number="TW-201610151" title="Methods for treating or preventing transthyretin (ttr) associated diseases"/><PatentFamily id="3328119" number="WO-2009073809" title="Carbohydrate conjugates as delivery agents for oligonucleotides"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbutus Biopharma Corp" id="1032153"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eastman Chemical Co" id="24112"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alnylam Pharmaceuticals Inc" id="29927"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>